PMID- 21788502 OWN - NLM STAT- MEDLINE DCOM- 20111123 LR - 20211020 IS - 1091-6490 (Electronic) IS - 0027-8424 (Print) IS - 0027-8424 (Linking) VI - 108 IP - 33 DP - 2011 Aug 16 TI - Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1. PG - 13379-86 LID - 10.1073/pnas.1110104108 [doi] AB - Aberrations in epigenetic processes, such as histone methylation, can cause cancer. Retinoblastoma binding protein 2 (RBP2; also called JARID1A or KDM5A) can demethylate tri- and dimethylated lysine 4 in histone H3, which are epigenetic marks for transcriptionally active chromatin, whereas the multiple endocrine neoplasia type 1 (MEN1) tumor suppressor promotes H3K4 methylation. Previous studies suggested that inhibition of RBP2 contributed to tumor suppression by the retinoblastoma protein (pRB). Here, we show that genetic ablation of Rbp2 decreases tumor formation and prolongs survival in Rb1(+/-) mice and Men1-defective mice. These studies link RBP2 histone demethylase activity to tumorigenesis and nominate RBP2 as a potential target for cancer therapy. FAU - Lin, Wenchu AU - Lin W AD - Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. FAU - Cao, Jian AU - Cao J FAU - Liu, Jiayun AU - Liu J FAU - Beshiri, Michael L AU - Beshiri ML FAU - Fujiwara, Yuko AU - Fujiwara Y FAU - Francis, Joshua AU - Francis J FAU - Cherniack, Andrew D AU - Cherniack AD FAU - Geisen, Christoph AU - Geisen C FAU - Blair, Lauren P AU - Blair LP FAU - Zou, Mike R AU - Zou MR FAU - Shen, Xiaohua AU - Shen X FAU - Kawamori, Dan AU - Kawamori D FAU - Liu, Zongzhi AU - Liu Z FAU - Grisanzio, Chiara AU - Grisanzio C FAU - Watanabe, Hideo AU - Watanabe H FAU - Minamishima, Yoji Andrew AU - Minamishima YA FAU - Zhang, Qing AU - Zhang Q FAU - Kulkarni, Rohit N AU - Kulkarni RN FAU - Signoretti, Sabina AU - Signoretti S FAU - Rodig, Scott J AU - Rodig SJ FAU - Bronson, Roderick T AU - Bronson RT FAU - Orkin, Stuart H AU - Orkin SH FAU - Tuck, David P AU - Tuck DP FAU - Benevolenskaya, Elizaveta V AU - Benevolenskaya EV FAU - Meyerson, Matthew AU - Meyerson M FAU - Kaelin, William G Jr AU - Kaelin WG Jr FAU - Yan, Qin AU - Yan Q LA - eng SI - GEO/GSE26446 SI - GEO/GSE26978 GR - CA16359/CA/NCI NIH HHS/United States GR - HHMI/Howard Hughes Medical Institute/United States GR - CA138631/CA/NCI NIH HHS/United States GR - R01 CA138631/CA/NCI NIH HHS/United States GR - R01 CA076120/CA/NCI NIH HHS/United States GR - P30 CA016359/CA/NCI NIH HHS/United States GR - CA076120/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20110725 PL - United States TA - Proc Natl Acad Sci U S A JT - Proceedings of the National Academy of Sciences of the United States of America JID - 7505876 RN - 0 (Enzyme Inhibitors) RN - 0 (Histones) RN - 0 (Men1 protein, mouse) RN - 0 (Proto-Oncogene Proteins) RN - 0 (Rbp2 protein, mouse) RN - 0 (Retinoblastoma Protein) RN - 0 (Retinol-Binding Proteins, Cellular) RN - EC 1.14.11.- (Histone Demethylases) SB - IM MH - Animals MH - Enzyme Inhibitors/therapeutic use MH - Epigenomics MH - Histone Demethylases MH - Histones/metabolism MH - Methylation MH - Mice MH - Mice, Knockout MH - Neoplasms/enzymology/etiology/*prevention & control MH - Proto-Oncogene Proteins/*deficiency MH - Retinoblastoma Protein/*deficiency MH - Retinol-Binding Proteins, Cellular/antagonists & inhibitors/*deficiency MH - Survival Rate PMC - PMC3158206 COIS- The authors declare no conflict of interest. EDAT- 2011/07/27 06:00 MHDA- 2011/12/13 00:00 PMCR- 2012/02/16 CRDT- 2011/07/27 06:00 PHST- 2011/07/27 06:00 [entrez] PHST- 2011/07/27 06:00 [pubmed] PHST- 2011/12/13 00:00 [medline] PHST- 2012/02/16 00:00 [pmc-release] AID - 1110104108 [pii] AID - 201110104 [pii] AID - 10.1073/pnas.1110104108 [doi] PST - ppublish SO - Proc Natl Acad Sci U S A. 2011 Aug 16;108(33):13379-86. doi: 10.1073/pnas.1110104108. Epub 2011 Jul 25.